Association of arginine vasopressin levels with outcomes and the effect of v2 blockade in patients hospitalized for heart failure with reduced ejection fraction insights from the everest trial

Circulation: Heart Failure

Volumn 6, Issue 1, 2013, Pages 47-52

  Lanfear, David E ^a   Sabbah, Hani N ^a   Goldsmith, Steven R ^a   Greene, Stephen J ^a,b   Ambrosy, Andrew P ^c   Fought, Angela J ^d   Kwasny, Mary J ^c   Swedberg, Karl ^e   Yancy, Clyde W ^c   Konstam, Marvin A ^f   Maggioni, Aldo P ^g   Zannad, Faiez ^h   Gheorghiade, Mihai ^c  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f TUFTS MEDICAL CENTER   (United States)

^g ANMCO RESEARCH CENTER   (Italy)

^h UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Drugs; Heart failure; Hormones; Outcomes

Indexed keywords

ARGIPRESSIN; TOLVAPTAN; VASOPRESSIN V2 RECEPTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; DRUG EFFICACY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEPTOR BLOCKING; RISK FACTOR; SURVIVAL; TREATMENT DURATION;

AGED; ARGININE VASOPRESSIN; BENZAZEPINES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INPATIENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, VASOPRESSIN; STROKE VOLUME; SURVIVAL RATE; UNITED STATES;

EID: 84873675675     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.970012     Document Type: Article

References (22)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385-1390.
3. Benedict CR, Johnstone DE, Weiner DH, Bourassa MG, Bittner V, Kay R, Kirlin P, Greenberg B, Kohn RM, Nicklas JM. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol. 1994;23:1410-1420.
4. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
5. Rouleau JL, Packer M, Moyé L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. J Am Coll Cardiol. 1994;24:583-591.
6. Ambrosy A, Goldsmith SR, Gheorghiade M. Tolvaptan for the treatment of heart failure: A review of the literature. Expert Opin Pharmacother. 2011;12:961-976.
7. Goldsmith SR, Cowley AW Jr, Francis GS, Cohn JN. Reflex control of osmotically stimulated vasopressin in normal humans. Am J Physiol. 1985;248(6 Pt 2):R660-R663.
8. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785-1791.
9. Finley JJ IV, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation. 2008;118:410-421.
10. Penit J, Faure M, Jard S. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am J Physiol. 1983;244:E72-E82.
11. Goldsmith SR. Vasopressin receptor antagonists: Mechanisms of action and potential effects in heart failure. Cleve Clin J Med. 2006; 73 Suppl 2:S20-23; discussion S30-23.
12. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319-1331.
13. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332-1343.
14. Orlandi C, Zimmer CA, Gheorghiade M. Tolvaptan for the treatment of hyponatremia and congestive heart failure. Future Cardiol. 2006;2:627-634.
15. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099-2112.
16. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA. 2004;291:1963-1971.
17. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation. 2003;107:2690-2696.
18. Pang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC Jr, Grinfeld L, Ouyang J, Udelson JE, Gheorghiade M; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009;30:2233-2240.
19. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with tolvaptan (EVEREST). J Card Fail. 2005;11:260-269.
20. Glick SM, Kagan A. Radioimmunoassay of arginine vasopressin. In: Jaffe BM, Behrman HR, eds. Methods of hormone radioimmunoassay. 2d ed. New York, NY: Academic Press; 1979: 1040.
21. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151-2159.
22. Pitt B, Gheorghiade M. Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: A potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial. Eur J Heart Fail. 2011;13:1261-1263.